Schroeder Discusses Limits on Use of Nondisclosure Agreements in Sexual Harassment Settlements
04 December 2017
Partner Don Schroeder is quoted in a Wired magazine article, “How to Pierce the Secrecy around Sexual Harassment Cases,” about proposed restrictions on the use of nondisclosure agreements in sexual harassment settlements.
Schroeder said employers would likely resist a requirement that they reveal prior complaints against an accused harasser when discussing a new settlement, saying parties already have the ability to ask about prior complaints if they file a lawsuit. “I’m not sure that an employer would even be inclined to settle a claim if they had to share upfront and before litigation all of that information,” he said.
Schroeder said employers would likely resist a requirement that they reveal prior complaints against an accused harasser when discussing a new settlement, saying parties already have the ability to ask about prior complaints if they file a lawsuit. “I’m not sure that an employer would even be inclined to settle a claim if they had to share upfront and before litigation all of that information,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”